Sartorius Stedim Biotech S.A. (SDMHF)
USD 201.5
(0.0%)
USD 201.5
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 749 Million EUR | -0.36% |
| 2022 | 751.7 Million EUR | 12.19% |
| 2021 | 670.02 Million EUR | 34.04% |
| 2020 | 499.88 Million EUR | 25.11% |
| 2019 | 399.56 Million EUR | 16.82% |
| 2018 | 342.03 Million EUR | 12.72% |
| 2017 | 303.44 Million EUR | 6.44% |
| 2016 | 285.07 Million EUR | 12.17% |
| 2015 | 254.14 Million EUR | 16.0% |
| 2014 | 219.08 Million EUR | 16.73% |
| 2013 | 187.69 Million EUR | 3.91% |
| 2012 | 180.62 Million EUR | 7.99% |
| 2011 | 167.26 Million EUR | 7.38% |
| 2010 | 155.76 Million EUR | 9.91% |
| 2009 | 141.72 Million EUR | 566780.0% |
| 2008 | 25 Thousand EUR | -99.98% |
| 2007 | 105.49 Million EUR | 24151.26% |
| 2006 | 435 Thousand EUR | -91.23% |
| 2005 | 4.95 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 193.5 Million EUR | -0.87% |
| 2024 Q1 | 195.2 Million EUR | -5.97% |
| 2024 Q3 | 204.7 Million EUR | 5.79% |
| 2023 Q4 | 207.6 Million EUR | 1.71% |
| 2023 Q3 | 204.1 Million EUR | -3.73% |
| 2023 Q2 | 212 Million EUR | -3.99% |
| 2023 Q1 | 220.8 Million EUR | 35.29% |
| 2023 FY | 749 Million EUR | -0.36% |
| 2022 FY | 751.7 Million EUR | 12.19% |
| 2022 Q4 | 163.2 Million EUR | -21.01% |
| 2022 Q1 | 193.2 Million EUR | 14.85% |
| 2022 Q3 | 206.6 Million EUR | 9.54% |
| 2022 Q2 | 188.6 Million EUR | -2.38% |
| 2021 Q1 | 154.3 Million EUR | 29.47% |
| 2021 Q2 | 167.4 Million EUR | 8.49% |
| 2021 Q3 | 180.1 Million EUR | 7.59% |
| 2021 Q4 | 168.22 Million EUR | -6.6% |
| 2021 FY | 670.02 Million EUR | 34.04% |
| 2020 Q4 | 119.18 Million EUR | -8.46% |
| 2020 Q3 | 130.2 Million EUR | 0.85% |
| 2020 Q2 | 129.1 Million EUR | 7.14% |
| 2020 Q1 | 120.5 Million EUR | 29.48% |
| 2020 FY | 499.88 Million EUR | 25.11% |
| 2019 Q3 | 107.8 Million EUR | 6.21% |
| 2019 Q4 | 93.06 Million EUR | -13.67% |
| 2019 FY | 399.56 Million EUR | 16.82% |
| 2019 Q2 | 101.5 Million EUR | 4.32% |
| 2019 Q1 | 97.3 Million EUR | 33.22% |
| 2018 Q2 | 87 Million EUR | -3.01% |
| 2018 Q1 | 89.7 Million EUR | 51.65% |
| 2018 FY | 342.03 Million EUR | 12.72% |
| 2018 Q4 | 73.03 Million EUR | -20.87% |
| 2018 Q3 | 92.3 Million EUR | 6.09% |
| 2017 Q2 | 81.3 Million EUR | 2.26% |
| 2017 FY | 303.44 Million EUR | 6.44% |
| 2017 Q4 | 59.14 Million EUR | -28.99% |
| 2017 Q3 | 83.3 Million EUR | 2.46% |
| 2017 Q1 | 79.5 Million EUR | -7.53% |
| 2016 Q1 | 74.6 Million EUR | -4.13% |
| 2016 Q4 | 85.97 Million EUR | 10.65% |
| 2016 FY | 285.07 Million EUR | 12.17% |
| 2016 Q3 | 77.7 Million EUR | 8.07% |
| 2016 Q2 | 71.9 Million EUR | -3.62% |
| 2015 Q4 | 77.81 Million EUR | 13.1% |
| 2015 Q1 | 61.5 Million EUR | -3.75% |
| 2015 Q2 | 69.4 Million EUR | 12.85% |
| 2015 FY | 254.14 Million EUR | 16.0% |
| 2015 Q3 | 68.8 Million EUR | -0.86% |
| 2014 Q4 | 63.89 Million EUR | 16.18% |
| 2014 Q2 | 55 Million EUR | 3.0% |
| 2014 Q3 | 55 Million EUR | 0.0% |
| 2014 FY | 219.08 Million EUR | 16.73% |
| 2014 Q1 | 53.4 Million EUR | 8.98% |
| 2013 Q2 | 50.2 Million EUR | 0.0% |
| 2013 Q4 | 48.99 Million EUR | 1.03% |
| 2013 Q3 | 48.49 Million EUR | -3.39% |
| 2013 FY | 187.69 Million EUR | 3.91% |
| 2012 FY | 180.62 Million EUR | 7.99% |
| 2012 Q2 | 48.1 Million EUR | 0.0% |
| 2011 Q2 | 44.8 Million EUR | 0.0% |
| 2011 FY | 167.26 Million EUR | 7.38% |
| 2010 FY | 155.76 Million EUR | 9.91% |
| 2010 Q2 | 39.9 Million EUR | 0.0% |
| 2009 FY | 141.72 Million EUR | 566780.0% |
| 2008 FY | 25 Thousand EUR | -99.98% |
| 2007 FY | 105.49 Million EUR | 24151.26% |
| 2006 FY | 435 Thousand EUR | -91.23% |
| 2005 FY | 4.95 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Medical Technologies Inc. | 2.86 Million USD | -26058.381% |
| Ansell Limited | 495.5 Million USD | -51.16% |
| Ansell Limited | 495.5 Million USD | -51.16% |
| BG Medicine, Inc. | - USD | -Infinity% |
| Biotage AB (publ) | 82.8 Million USD | -804.548% |
| BioLife Sciences Inc. | - USD | -Infinity% |
| CB Scientific, Inc. | 1.73 Million USD | -43175.886% |
| Psykey, Inc. | 1.21 Million USD | -61623.308% |
| ConvaTec Group Plc | 910.31 Million USD | 17.721% |
| ConvaTec Group Plc | 872.5 Million USD | 14.155% |
| Encision Inc. | 3.77 Million USD | -19731.892% |
| Golden Valley Development, Inc | 141.81 Thousand USD | -528067.773% |
| Hear AtLast Holdings, Inc. | 109.93 Thousand USD | -681236.475% |
| Innovative MedTech Inc. | 6.09 Million USD | -12180.7% |
| LifePoint, Inc. | 7.42 Million USD | -9989.078% |
| Medite Cancer Diagnostics, Inc. | 6.34 Million USD | -11697.133% |
| Paradigm Medical Industries, Inc. | 855 Thousand USD | -87502.339% |
| QuantRx Biomedical Corporation | - USD | -Infinity% |
| Remedent, Inc. | 726.13 Thousand USD | -103049.006% |
| Reflect Scientific, Inc. | 1.06 Million USD | -70314.657% |
| SmileDirectClub, Inc. | 517 Million USD | -44.873% |
| Sector 10, Inc. | 39.84 Thousand USD | -1879731.342% |
| Shandong Weigao Group Medical Polymer Company Limited | 6.64 Billion USD | 88.725% |
| SheerVision, Inc. | 2.33 Million USD | -32023.381% |
| United Health Products, Inc. | 2.42 Million USD | -30767.009% |
| Vasamed, Inc. | 4.67 Million USD | -15928.542% |
| Wearable Health Solutions, Inc. | 2.56 Million USD | -29137.209% |
| Yubo International Biotech Limited | 1.25 Million USD | -59444.867% |